AR090739A1 - Nicotinamidas 6-amino sustituidas con un grupo que contiene oh como moduladores de kcnq2/3 - Google Patents

Nicotinamidas 6-amino sustituidas con un grupo que contiene oh como moduladores de kcnq2/3

Info

Publication number
AR090739A1
AR090739A1 ARP130101283A ARP130101283A AR090739A1 AR 090739 A1 AR090739 A1 AR 090739A1 AR P130101283 A ARP130101283 A AR P130101283A AR P130101283 A ARP130101283 A AR P130101283A AR 090739 A1 AR090739 A1 AR 090739A1
Authority
AR
Argentina
Prior art keywords
residue
aliphatic residue
aliphatic
mono
polysubstituted
Prior art date
Application number
ARP130101283A
Other languages
English (en)
Spanish (es)
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR090739A1 publication Critical patent/AR090739A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ARP130101283A 2012-04-18 2013-04-18 Nicotinamidas 6-amino sustituidas con un grupo que contiene oh como moduladores de kcnq2/3 AR090739A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12002709 2012-04-18

Publications (1)

Publication Number Publication Date
AR090739A1 true AR090739A1 (es) 2014-12-03

Family

ID=48227140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101283A AR090739A1 (es) 2012-04-18 2013-04-18 Nicotinamidas 6-amino sustituidas con un grupo que contiene oh como moduladores de kcnq2/3

Country Status (21)

Country Link
EP (1) EP2888233B1 (enExample)
JP (1) JP6033403B2 (enExample)
CN (1) CN104428287A (enExample)
AR (1) AR090739A1 (enExample)
AU (1) AU2013248637A1 (enExample)
BR (1) BR112014025840A2 (enExample)
CA (1) CA2870573A1 (enExample)
CY (1) CY1118255T1 (enExample)
DK (1) DK2888233T3 (enExample)
EA (1) EA201401142A1 (enExample)
ES (1) ES2605947T3 (enExample)
HK (1) HK1210173A1 (enExample)
HR (1) HRP20161424T1 (enExample)
HU (1) HUE030859T2 (enExample)
IL (1) IL235030A0 (enExample)
LT (1) LT2888233T (enExample)
MX (1) MX2014012494A (enExample)
PT (1) PT2888233T (enExample)
RS (1) RS55466B1 (enExample)
SI (1) SI2888233T1 (enExample)
WO (1) WO2013156154A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3447047A1 (en) * 2016-04-22 2019-02-27 ONO Pharmaceutical Co., Ltd. Crystal polymorphism of kcnq 2-5 channel activator
WO2019130185A1 (en) * 2017-12-29 2019-07-04 3M Innovative Properties Company Thermally curable two part processing adhesive composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
CZ20032233A3 (cs) 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
MXPA03007397A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
JP2012506395A (ja) 2008-10-24 2012-03-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み、てんかん、及び尿失禁の治療のためのkcnq2/3モジュレーターとしての置換された4,5,6,7−テトラヒドロチエノピリジン
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
CA2815131C (en) * 2010-10-20 2020-06-09 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as kcnq2/3 modulators

Also Published As

Publication number Publication date
WO2013156154A1 (en) 2013-10-24
EP2888233B1 (en) 2016-09-28
CN104428287A (zh) 2015-03-18
AU2013248637A1 (en) 2014-12-04
BR112014025840A2 (pt) 2017-07-18
CA2870573A1 (en) 2013-10-24
JP2015514728A (ja) 2015-05-21
JP6033403B2 (ja) 2016-11-30
EA201401142A1 (ru) 2015-03-31
CY1118255T1 (el) 2017-06-28
HRP20161424T1 (hr) 2016-12-16
HK1210173A1 (en) 2016-04-15
DK2888233T3 (en) 2017-01-09
SI2888233T1 (sl) 2016-12-30
HUE030859T2 (en) 2017-06-28
EP2888233A1 (en) 2015-07-01
PT2888233T (pt) 2017-01-04
MX2014012494A (es) 2015-01-15
ES2605947T3 (es) 2017-03-17
RS55466B1 (sr) 2017-04-28
LT2888233T (lt) 2017-01-10
IL235030A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR107154A1 (es) Estimuladores de guanilato ciclasa soluble
AR092279A1 (es) Pirrol carboxamidas fluorometilo sustituidas
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
AR102389A1 (es) Profármacos de carbidopa y l-dopa y métodos de uso de los mismos, kit
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
AR058388A1 (es) DERIVADOS DE COMPUESTOS AROMATICOS SUSTITUIDOS uTILES PARA TRASTORNOS RESPIRATORIOS , COMPOSICIONES FARMACÉUTICAS Y PROCESOS PARA SU PREPARACIoN
AR083477A1 (es) 6-aminonicotinamidas sustituidas utiles para el tratamiento del dolor y composiciones farmaceuticas que las contienen
AR107828A1 (es) 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR094735A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
AR122096A2 (es) Compuestos profármacos de creatina y composiciones que los comprenden
AR106296A1 (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo
AR100715A1 (es) Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
AR120578A1 (es) DERIVADOS DE BENCILAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 (TGFbRI) / ALK5
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
EA202190285A1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
AR094412A1 (es) Carboxamidas basadas en pirazolilo i
AR082732A1 (es) 2-oxiquinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3
AR082734A1 (es) Quinolino-3-carboxamidas sustituidas como moduladores de kcnq2/3
AR086803A1 (es) Derivados de oxazetidinas, composiciones farmaceuticas y cosmeticas que los contienen y uso de los mismos para tratar enfermedades dermatologicas fundamentalmente, y del aparato respiratorio, digestivo y cardiovascular, entre otras

Legal Events

Date Code Title Description
FB Suspension of granting procedure